Knee stem cell therapy is one of the most heavily marketed applications of regenerative medicine, which makes it one of the areas where separating genuine clinical evidence from optimistic advertising matters most. This guide reviews what research actually shows, broken down by condition type, cell source, and protocol, so you can have an informed conversation before deciding whether an assessment is worth pursuing.
Knee Osteoarthritis Versus Cartilage Injury
These two conditions are often discussed together, but they are clinically distinct, and the evidence base differs for each.
| Condition | What It Is | Relevance to Stem Cell Research |
| Knee osteoarthritis (OA) | Progressive, degenerative wear of joint cartilage, usually age-related, affecting the whole joint | Larger body of MSC research; results modest and inconsistent in bigger trials |
| Focal cartilage injury | A specific, localised defect, often from trauma or sports injury, in an otherwise healthy joint | Different biological context; some studies suggest better regenerative potential due to surrounding healthy tissue |
This distinction matters because a treatment protocol and realistic expectation for a contained, traumatic cartilage defect in a younger, otherwise healthy knee is not the same conversation as treatment for diffuse, degenerative OA in an older joint with widespread wear.
Evidence by Cell Source
Not all “stem cell” knee treatments use the same cells, and outcomes reported in research are tied closely to which source and preparation was actually used.
| Cell Source | Description | General Evidence Pattern |
| Autologous bone marrow aspirate concentrate (BMAC) | Patient’s own bone marrow, processed same-day | Small trials, mixed results; one notable US comparative trial (MILES) found no clear advantage over corticosteroid injection at one year |
| Autologous adipose-derived cells | Patient’s own fat tissue, variable processing | Some positive small studies; quality and concentration vary significantly by technique |
| Culture-expanded mesenchymal stem cells (MSCs) | Cells grown and expanded in a laboratory to a defined dose, from bone marrow, adipose, or umbilical cord tissue | More standardised dosing; several controlled trials report modest pain and function improvement, though results remain inconsistent across studies |
| Umbilical cord-derived MSCs (e.g. Wharton’s Jelly) | Donor-derived, laboratory-cultured cells | Growing body of research; proposed advantages include younger cell source and standardised, higher-quality dosing compared to some same-day autologous preparations |
This is why asking specifically which cell source and preparation method any clinic uses matters more than asking generally “do you offer stem cell therapy for knees.” The answer changes what evidence is actually relevant to your decision.
Protocol Differences That Affect Outcomes
Beyond cell source, several protocol variables differ meaningfully between clinics and studies, and these differences make it difficult to generalise results from one setting to another:
- Cell dose – studies have used widely varying cell counts per injection, and some research suggests a possible dose-response relationship
- Number of sessions – single-injection versus multi-session protocols
- Injection technique – ultrasound-guided versus landmark-guided administration
- Concurrent rehabilitation – whether structured physiotherapy accompanies the injection, which may influence functional outcomes
- Patient selection criteria – the OA grade, age range, and health status of patients included in a given study or protocol
A result reported by one hospital or research group using a specific protocol should not be assumed to apply automatically to a different clinic using a different cell source, dose, or technique. This is a genuine limitation worth raising directly whenever reviewing published results or hospital-reported outcomes.
Risks to Understand
| Risk | Relevance |
| Post-injection pain, swelling, or stiffness | Common, usually temporary |
| Joint infection | Low but real risk with any intra-articular injection |
| Allergic or immune reaction | Rare, more relevant with donor-derived cell sources |
| Uncertain durability | Benefit, where present, often diminishes over 12 to 24 months in available studies |
| Opportunity cost | Time and expense spent on a treatment with evidence still developing, versus established options |
Alternatives Worth Comparing
Before deciding whether a stem cell assessment is the right next step, it’s worth understanding how it compares to other established options for knee OA:
| Option | Evidence Level | General Role |
| Physiotherapy and exercise | Strong | First-line for nearly all OA stages |
| Corticosteroid injection | Moderate | Short-term relief for flare-ups |
| Hyaluronic acid injection | Moderate, debated | Some symptomatic benefit reported |
| PRP injection | Moderate, growing | Increasingly used, generally lower cost than cultured MSC therapy |
| MSC-based injection | Emerging | Evidence still developing; results vary by protocol and cell source |
| Knee replacement surgery | Strong | Definitive option for advanced, severe OA |
How This Affects Surgery Decisions
One of the most important, and most often glossed-over, questions is whether pursuing stem cell therapy might delay a surgery decision that’s otherwise appropriate. For patients with advanced, bone-on-bone OA, current evidence does not support stem cell therapy as a reliable way to avoid or significantly postpone knee replacement. For patients with earlier-stage OA still exploring non-surgical options, it may be one option to discuss among several, not a presumed better alternative to the established conservative pathway. This decision should always be made in coordination with an orthopaedic surgeon familiar with your joint’s actual condition and imaging.
How to Read Clinic and Hospital Claims Critically
Because knee stem cell marketing is widespread, it’s worth applying a consistent filter to any claim you come across, including ones made by any individual clinic:
| Question to Ask | Why It Matters |
| Is this based on a published, controlled study, or a case series? | Case series and testimonials carry far less weight than controlled trials |
| What cell source and dose was actually used? | Results don’t transfer automatically between different sources and doses |
| What OA grade were the study participants? | A result in early-stage OA may not apply to advanced, bone-on-bone disease |
| How long was the follow-up period? | Short-term results can overstate how durable any benefit actually is |
| Was there a control group? | Knee pain responds strongly to placebo, making uncontrolled studies hard to interpret |
Holding any source, including this page, to this standard is a reasonable way to approach a decision this significant.
Frequently Asked Questions
Is stem cell therapy proven to work better than surgery for knee OA?
No. For advanced OA, knee replacement remains the evidence-backed definitive option. Stem cell therapy has not been shown to reliably replace or delay necessary surgery.
Does a hospital’s published results apply to any clinic offering stem cell therapy?
Not automatically. Results depend heavily on the specific cell source, dose, and protocol used, which vary significantly between institutions and cannot be generalised.
Which cell source has the strongest evidence for knee OA?
No single source is definitively proven superior. Culture-expanded MSCs offer more standardised dosing, but results across all sources remain modest and inconsistent.
Is cartilage injury treatment the same as osteoarthritis treatment?
No. These are different clinical situations with different biological contexts, and evidence from one should not be assumed to apply directly to the other.
How long do benefits typically last if there is improvement?
Available studies often show benefits diminishing over 12 to 24 months, though this varies by patient, protocol, and the severity of underlying OA.
Should I try this before considering knee replacement?
This depends on your OA grade and overall joint condition. It’s a decision to make with your orthopaedic surgeon, not a default alternative to surgery.
Discuss Your Knee With Our Team
If you’d like to understand how this evidence applies to your specific knee and OA grade, request an assessment and bring any recent imaging you have. You can also learn more about our stem cell therapy programme.